<<Optimer Pharma and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today that the European Commission has granted Marketing Authorization (MA) for DIFICLIR(TM)(fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea >>
No,really, it's expected.....so much short money riding here , my opinion only,but,think the shorts could not allow this to spike normally as a reaction to the news. Pays to be contrairian in this market. They were lucky that market had an off day or optr would have risen considerably!!! Didnt take much work for them to drive it down. Guess is that it's just going to create a bigger/faster upward pps move in the very near future!!!!!